Barbara Büchel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Barbara Büchel has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Carlo Rodolfo Largiadèr
Department of Clinical Chemistry, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
3 shared publications - Markus Joerger
Kantonsspital St. Gallen
2 shared publications B. Pfister
Clinical Research Facility, Department of Medical Oncology and Hematology, Cantonal Hospital, St. Gallen, Switzerland
1 shared publicationClaudia Bühr
Department of Chemistry and Biochemistry University of Bern Freiestraße 3 CH‐3012 Bern Switzerland
1 shared publicationD. Köberle
Clinical Research Facility, Department of Medical Oncology and Hematology, Cantonal Hospital, St. Gallen, Switzerland
1 shared publicationF. Mueller
Department of Internal Medicine, Cantonal Hospital, St Gallen, Switzerland
1 shared publication
Latest Publications
- 14 February 2013
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 51 (8) , 1681-1688
Comparative evaluation of the My5-FU™ immunoassay and LC-MS/MS in monitoring the 5-fluorouracil plasma levels in cancer patients
Background: Chemotherapies of solid tumors commonly include 5-fluorouracil (5-FU). With standard doses of 5-FU, substantial inter-patient variability has been observed in exposure levels and treatment response. Recently, improved outcomes in colorectal cancer patients due to pharmacokinetically guided 5-FU dosing were reported. We aimed at establishing a rapid and sensitive method for monitoring 5-FU plasma levels in cancer patients in our routine clinical practice. Methods: Performance of the Saladax My5-FU™ immunoassay was evaluated on the Roche Cobas® Integra 800 analyzer. Subsequently, 5-FU concentrations of 247 clinical plasma samples obtained with this assay were compared to the results obtained by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and other commonly used clinical analyzers (Olympus AU400, Roche Cobas c6000, and Thermo Fisher CDx90). Results: The My-FU assay was successfully validated on the Cobas Integra 800 analyzer in terms of linearity, precision, accuracy, recovery, interference, sample carryover, and dilution integrity. Method comparison between the Cobas Integra 800 and LC-MS/MS revealed a proportional bias of 7% towards higher values measured with the My5-FU assay. However, when the Cobas Integra 800 was compared to three other clinical analyzers in addition to LC-MS/MS including 50 samples representing the typical clinical range of 5-FU plasma concentrations, only a small proportional bias (≤1.6%) and a constant bias below the limit of detection was observed. Conclusions: The My5-FU assay demonstrated robust and highly comparable performance on different analyzers. Therefore, the assay is suitable for monitoring 5-FU plasma levels in routine clinical practice and may contribute to improved efficacy and safety of commonly used 5-FU-based chemotherapies.
- 14 February 2013
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 51 (8) , 1681-1688
Comparative evaluation of the My5-FU™ immunoassay and LC-MS/MS in monitoring the 5-fluorouracil plasma levels in cancer patients
Background: Chemotherapies of solid tumors commonly include 5-fluorouracil (5-FU). With standard doses of 5-FU, substantial inter-patient variability has been observed in exposure levels and treatment response. Recently, improved outcomes in colorectal cancer patients due to pharmacokinetically guided 5-FU dosing were reported. We aimed at establishing a rapid and sensitive method for monitoring 5-FU plasma levels in cancer patients in our routine clinical practice. Methods: Performance of the Saladax My5-FU™ immunoassay was evaluated on the Roche Cobas® Integra 800 analyzer. Subsequently, 5-FU concentrations of 247 clinical plasma samples obtained with this assay were compared to the results obtained by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and other commonly used clinical analyzers (Olympus AU400, Roche Cobas c6000, and Thermo Fisher CDx90). Results: The My-FU assay was successfully validated on the Cobas Integra 800 analyzer in terms of linearity, precision, accuracy, recovery, interference, sample carryover, and dilution integrity. Method comparison between the Cobas Integra 800 and LC-MS/MS revealed a proportional bias of 7% towards higher values measured with the My5-FU assay. However, when the Cobas Integra 800 was compared to three other clinical analyzers in addition to LC-MS/MS including 50 samples representing the typical clinical range of 5-FU plasma concentrations, only a small proportional bias (≤1.6%) and a constant bias below the limit of detection was observed. Conclusions: The My5-FU assay demonstrated robust and highly comparable performance on different analyzers. Therefore, the assay is suitable for monitoring 5-FU plasma levels in routine clinical practice and may contribute to improved efficacy and safety of commonly used 5-FU-based chemotherapies.
- 9 November 2012
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 71 (2) , 361-370
Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study
Background This study was initiated to assess the quantitative impact of patient anthropometrics and dihydropyrimidine dehydrogenase (DPYD) mutations on the pharmacokinetics (PK) of 5-fluorouracil (5FU) and to explore limited sampling strategies of 5FU. Patients and methods We included 32 patients with gastrointestinal malignancies, receiving 46-h continuous-infusional 5FU and performed PK-sampling at baseline, 15, 30, 45 min, 1 and 2 h after the start of infusion and at the end of infusion, for 2 subsequent cycles. Plasma concentrations of 5FU, 5-fluorodihydrouracil (5FUH2), uracil (U) and 5,6-dihydrouracil (UH2) were determined using LC–MS/MS and submitted to population PK analysis using nonlinear mixed-effects modeling. Broad genotyping of DPYD was performed, and the potential impact of the DPYD genotype on the elimination of 5FU was assessed. Limited sampling strategies were evaluated for their accuracy to predict steady-state concentrations of 5FU (CSS5FU), using data simulations based on the final PK-model. Results The area-under-the concentration–time curve of 5FU (AUC5FU) was found to be 30 mg h/L in 7 occasions (12 %). Men had a 26 % higher elimination of 5FU and a 18 % higher apparent elimination of 5FUH2. Accordingly, women had a higher AUC5FU compared to men (22 vs. 18 mg h/L, p = 0.04). No DPYD risk variants were found, and the DPYD variants detected (c.496A>G, c.1601G>A, c.1627A>G) were not significantly associated with the elimination of 5FU. Individual baseline UH2/U ratio was significantly associated with AUC5FU (R = −0.49, p < 0.001). Limited sampling strategies with time-points 5FU. Female gender was the only predictor of nausea/emesis in the multivariate model. Conclusions Gender-specific elimination of 5FU is supported by the present data and may partly explain the gender-specific association between DPYD risk variants and 5FU-specific toxicity.
- 9 November 2012
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 71 (2) , 361-370
Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study
Background This study was initiated to assess the quantitative impact of patient anthropometrics and dihydropyrimidine dehydrogenase (DPYD) mutations on the pharmacokinetics (PK) of 5-fluorouracil (5FU) and to explore limited sampling strategies of 5FU. Patients and methods We included 32 patients with gastrointestinal malignancies, receiving 46-h continuous-infusional 5FU and performed PK-sampling at baseline, 15, 30, 45 min, 1 and 2 h after the start of infusion and at the end of infusion, for 2 subsequent cycles. Plasma concentrations of 5FU, 5-fluorodihydrouracil (5FUH2), uracil (U) and 5,6-dihydrouracil (UH2) were determined using LC–MS/MS and submitted to population PK analysis using nonlinear mixed-effects modeling. Broad genotyping of DPYD was performed, and the potential impact of the DPYD genotype on the elimination of 5FU was assessed. Limited sampling strategies were evaluated for their accuracy to predict steady-state concentrations of 5FU (CSS5FU), using data simulations based on the final PK-model. Results The area-under-the concentration–time curve of 5FU (AUC5FU) was found to be 30 mg h/L in 7 occasions (12 %). Men had a 26 % higher elimination of 5FU and a 18 % higher apparent elimination of 5FUH2. Accordingly, women had a higher AUC5FU compared to men (22 vs. 18 mg h/L, p = 0.04). No DPYD risk variants were found, and the DPYD variants detected (c.496A>G, c.1601G>A, c.1627A>G) were not significantly associated with the elimination of 5FU. Individual baseline UH2/U ratio was significantly associated with AUC5FU (R = −0.49, p < 0.001). Limited sampling strategies with time-points 5FU. Female gender was the only predictor of nausea/emesis in the multivariate model. Conclusions Gender-specific elimination of 5FU is supported by the present data and may partly explain the gender-specific association between DPYD risk variants and 5FU-specific toxicity.
- 27 March 2012
- Published by Wiley in Biomedical Chromatography
- Vol. 27 (1) , 7-16
LC‐MS/MS method for simultaneous analysis of uracil, 5,6‐dihydrouracil, 5‐fluorouracil and 5‐fluoro‐5,6‐dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients
The chemotherapeutic drug 5‐fluorouracil (5‐FU) is widely used for treating solid tumors. Response to 5‐FU treatment is variable with 10–30% of patients experiencing serious toxicity partly explained by reduced activity of dihydropyrimidine dehydrogenase (DPD). DPD converts endogenous uracil (U) into 5,6‐dihydrouracil (UH2), and analogously, 5‐FU into 5‐fluoro‐5,6‐dihydrouracil (5‐FUH2). Combined quantification of U and UH2 with 5‐FU and 5‐FUH2 may provide a pre‐therapeutic assessment of DPD activity and further guide drug dosing during therapy. Here, we report the development of a liquid chromatography–tandem mass spectrometry assay for simultaneous quantification of U, UH2, 5‐FU and 5‐FUH2 in human plasma. Samples were prepared by liquid–liquid extraction with 10:1 ethyl acetate‐2‐propanol (v/v). The evaporated samples were reconstituted in 0.1% formic acid and 10 μL aliquots were injected into the HPLC system. Analyte separation was achieved on an Atlantis dC18 column with a mobile phase consisting of 1.0 mm ammonium acetate, 0.5 mm formic acid and 3.3% methanol. Positively ionized analytes were detected by multiple reaction monitoring. The analytical response was linear in the range 0.01–10 μm for U, 0.1–10 μm for UH2, 0.1–75 μm for 5‐FU and 0.75–75 μm for 5‐FUH2, covering the expected concentration ranges in plasma. The method was validated following the FDA guidelines and applied to clinical samples obtained from ten 5‐FU‐treated colorectal cancer patients. The present method merges the analysis of 5‐FU pharmacokinetics and DPD activity into a single assay representing a valuable tool to improve the efficacy and safety of 5‐FU‐based chemotherapy. Copyright © 2012 John Wiley & Sons, Ltd.
- 27 March 2012
- Published by Wiley in Biomedical Chromatography
- Vol. 27 (1) , 7-16
LC‐MS/MS method for simultaneous analysis of uracil, 5,6‐dihydrouracil, 5‐fluorouracil and 5‐fluoro‐5,6‐dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients
The chemotherapeutic drug 5‐fluorouracil (5‐FU) is widely used for treating solid tumors. Response to 5‐FU treatment is variable with 10–30% of patients experiencing serious toxicity partly explained by reduced activity of dihydropyrimidine dehydrogenase (DPD). DPD converts endogenous uracil (U) into 5,6‐dihydrouracil (UH2), and analogously, 5‐FU into 5‐fluoro‐5,6‐dihydrouracil (5‐FUH2). Combined quantification of U and UH2 with 5‐FU and 5‐FUH2 may provide a pre‐therapeutic assessment of DPD activity and further guide drug dosing during therapy. Here, we report the development of a liquid chromatography–tandem mass spectrometry assay for simultaneous quantification of U, UH2, 5‐FU and 5‐FUH2 in human plasma. Samples were prepared by liquid–liquid extraction with 10:1 ethyl acetate‐2‐propanol (v/v). The evaporated samples were reconstituted in 0.1% formic acid and 10 μL aliquots were injected into the HPLC system. Analyte separation was achieved on an Atlantis dC18 column with a mobile phase consisting of 1.0 mm ammonium acetate, 0.5 mm formic acid and 3.3% methanol. Positively ionized analytes were detected by multiple reaction monitoring. The analytical response was linear in the range 0.01–10 μm for U, 0.1–10 μm for UH2, 0.1–75 μm for 5‐FU and 0.75–75 μm for 5‐FUH2, covering the expected concentration ranges in plasma. The method was validated following the FDA guidelines and applied to clinical samples obtained from ten 5‐FU‐treated colorectal cancer patients. The present method merges the analysis of 5‐FU pharmacokinetics and DPD activity into a single assay representing a valuable tool to improve the efficacy and safety of 5‐FU‐based chemotherapy. Copyright © 2012 John Wiley & Sons, Ltd.
- Open Access
- 1 January 2002
- Published by Springer Nature in Die Innere Medizin
- Vol. 43 (1) , 105-109
Unklares Fieber, Kopf- und Muskelschmerzen, Hämoptoe, Hepatosplenomegalie und Ikterus Zwei Fallbeispiele
Die Leptospirose kommt in der Schweiz aufgrund der klimatischen Verhältnisse selten vor, trotzdem wird die Inzidenz dieser Krankheit unterschätzt. Das klinische Bild ist vielfältig. Die Differentialdiagnose reicht von einer grippeähnlichen Erkrankung bis hin zur akut verlaufenden Systemerkrankung. Diese Tatsache erfordert aufgrund der therapeutischen Konsequenz, die Durchführung einer intensiven und häufig auch invasiven Diagnostik, welche letztlich oft unergiebig bleibt. Neue und vor allem schnellere diagnostische Möglichkeiten mittels PCR aus Blut, Liquor und Urin werden diskutiert, sind aber noch nicht etabliert. Eine antibiotische Therapie wird je nach Verlaufsform kontrovers beurteilt.
- 1 January 2002
- Published by Springer Nature in Die Innere Medizin
- Vol. 43 (1) , 105-109
Open AccessUnklares Fieber, Kopf- und Muskelschmerzen, Hämoptoe, Hepatosplenomegalie und Ikterus Zwei Fallbeispiele
Die Leptospirose kommt in der Schweiz aufgrund der klimatischen Verhältnisse selten vor, trotzdem wird die Inzidenz dieser Krankheit unterschätzt. Das klinische Bild ist vielfältig. Die Differentialdiagnose reicht von einer grippeähnlichen Erkrankung bis hin zur akut verlaufenden Systemerkrankung. Diese Tatsache erfordert aufgrund der therapeutischen Konsequenz, die Durchführung einer intensiven und häufig auch invasiven Diagnostik, welche letztlich oft unergiebig bleibt. Neue und vor allem schnellere diagnostische Möglichkeiten mittels PCR aus Blut, Liquor und Urin werden diskutiert, sind aber noch nicht etabliert. Eine antibiotische Therapie wird je nach Verlaufsform kontrovers beurteilt.